Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,38
KB-1,24
PKN109,35106,2-0,05
Msft2,55
IBM-0,97
DCX70,9570,980,17
PFE2,03
16.12.2017 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.12.2017
Vital Therapies (NASDAQ Cons)
Závěr k 15.12.2017 Změna (%) Změna (USD) Objem obchodů (ks)
5,55 0,91 0,05 997 045
After-hours16.12.2017 2:10:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
5,55 - - 0,91 0,05
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.12.2017
Popis společnosti
Obecné informace
Název společnostiVital Therapies Inc
TickerVTL
Kmenové akcie:Ordinary Shares
RICVTL.O
ISINUS92847R1041
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 31.1.2017 87
Akcie v oběhu k 20.10.2017 42 207 376
Počet akcionářů k 31.12.2016 71
MěnaUSD
Kontaktní informace
Ulice15010 Avenue of Science Ste 200
MěstoSAN DIEGO
PSČ92128-3421
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 586 736 840
Fax13026555049

Business Summary: Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company's ELAD System consists of approximately four disposable ELAD C3A cell cartridges.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Vital Therapies Inc revenues was not reported. Net loss increased 28% to $37.5M. Higher net loss reflects Research & Developmenmt increase of 41% to $27.9M (expense), Stock-based Compensation in SGA increase of 20% to $2.3M (expense), General & Administrative expenses increase of 1% to $6.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.94 to -$0.98.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSInVitro Diagnostic Substance Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICDiagnostic Substances
SICCommercial Physical Research



  • Poslední aktualizace: 18.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardFaheem Hasnain586.9.20176.9.2017
Chief Executive Officer, DirectorRussell Cox543.1.20183.1.2018
Chief Executive Officer, DirectorTerence Winters746.9.2017
Chief Financial OfficerMichael Swanson55
Executive Vice President, Chief Technical OfficerRobert Ashley57
Executive Vice President, Chief Business OfficerDuane Nash46
Chief Administrative OfficerAron Stern61
Vice President - Clinical OperationsAndrew Henry50
Vice President - Regulatory Affairs and Quality AssuranceAndrea Loewen-Rodriguez47
Vice President - ManufacturingRichard Murawski66